What is MPLT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.49B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MPLT?

P/E (TTM) is n/a and 52-week range is $8.92 to $40.43 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MPLT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MPLT?

The company profile lists net income (TTM) near $-569M, EPS (TTM) near $-12.54 when available from the market-data feed. Figures are informational and may lag live markets.

Where is MapLight Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Redwood City, California, US, 45.4M shares outstanding, ISIN US56565P1030 when available from company profile and filing metadata.

MapLight Therapeutics Inc

$MPLT

Health Care · Biotechnology

Run Scenarios

$8.83

-3.50%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. The company is headquartered in Redwood City, California and currently employs 133 full-time employees. The company went IPO on 2025-10-27. The firm is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. The company is also advancing two preclinical programs, ML-021 and ML-009.

Employees

133

Website

maplightrx.com/

IPO

2025-10-27

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)